Outlaw DNA [Gene Doping in Sports]
By Gretchen Reynolds,
New York Times
| 06. 04. 2007
It was a single line from a longer e-mail message. But when read into the record by prosecutors at the drug trial last year of the German track coach Thomas Springstein, it caused a sensation. "The new Repoxygen is hard to get," Springstein had written. "Please give me new instructions soon so that I can order the product before Christmas."
Until that day in the courtroom, Repoxygen was an obscure gene-therapy drug developed at a pharmaceutical lab in Oxford, England, to fight anemia. The lab shelved the product when it seemed unlikely to be profitable. Once it was mentioned in court in January 2006, however, Repoxygen vaulted to celebrity-drug status in Europe. Newspapers and Web sites ran dozens of stories about the imminent danger of the therapy. "The moment that e-mail was presented in open court," a columnist wrote in the weekend paper Scotland on Sunday, was when the "era of genetic doping . . . arrived."
Repoxygen works by worming a specialized gene into its host’s DNA. In the right circumstances, the gene directs cells to start making extra...
Related Articles
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Nick Paul Taylor, Fierce Biotech | 01.09.2026
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist Fyodor Urnov, Ph.D., to launch Aurora...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...